title: Prognostic value of ventricular arrhythmias in systemic hypertension.
abstract: OBJECTIVE
  Hypertensive left ventricular hypertrophy is associated with an increased risk of arrhythmias and mortality. However, no clinical study has demonstrated a significant relationship between ventricular arrhythmias and mortality in systemic hypertension.
  
  
  METHODS
  To evaluate the prognostic value of arrhythmogenic markers, we included, prospectively, 214 hypertensive patients aged (mean+/-SD) 59.1+/-12.8 years, without symptomatic coronary disease, myocardial infarction, systolic dysfunction or electrolyte disturbances. At inclusion, a 12-lead electrocardiogram (ECG) with QT dispersion calculation, a 24 h Holter ECG (204 patients) with Lown classification of ventricular arrhythmias, echocardiography (reliable in 187 patients) and a signal-averaged ECG (125 patients) with ventricular late potentials were recorded.
  
  
  RESULTS
  At baseline, echocardiographic left ventricular hypertrophy was found in 63 patients (33.7%). Non-sustained ventricular tachycardia (Lown class IVb) was recorded in 33 patients (16.2%) and late potentials in 27 patients (21.6%). After a mean follow-up of 42.4+/-26.8 months, all-cause mortality was 11.2% (24 patients); 17 patients died of cardiac causes (7.9%); of these, nine (4.2%) died suddenly. In univariate analysis, age, Lown class IVb and a QT dispersion > 80 ms were significantly related to global, cardiac and sudden death (P < 0.01). The left ventricular mass index was related to cardiac mortality (P= 0.002). In multivariate analysis, only Lown class IVb was an independent predictor of global and cardiac mortality, increasing the risk of global death 2.6-fold (95% confidence interval 1.2-6.0) and cardiac death 3.5-fold (95% confidence interval 1.2-9.7).
  
  
  CONCLUSIONS
  In hypertensive patients the presence of non-sustained ventricular tachycardia has prognostic value.
authors.affiliation: Cardiology Department, Rangueil University Hospital, Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Galinier
authors.forename: S
authors.initials: S
authors.lastname: Balanescu
authors.forename: J
authors.initials: J
authors.lastname: Fourcade
authors.forename: M
authors.initials: M
authors.lastname: Dorobantu
authors.forename: S
authors.initials: S
authors.lastname: Boveda
authors.forename: P
authors.initials: P
authors.lastname: Massabuau
authors.forename: P
authors.initials: P
authors.lastname: Cabrol
authors.forename: B
authors.initials: B
authors.lastname: Dongay
authors.forename: J M
authors.initials: JM
authors.lastname: Fauvel
authors.forename: J P
authors.initials: JP
authors.lastname: Bounhoure
mesh_terms: D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality